Health · 1 view
Tumor markers reveal which HER2+ breast cancer patients may respond to less intensive chemotherapy
The Journal of Clinical Oncology has published secondary results from the ECOG-ACRIN Cancer Research Group's CompassHER2-pCR clinical trial (EA1181, NCT04266249).
Summary
The Journal of Clinical Oncology has published secondary results from the ECOG-ACRIN Cancer Research Group's CompassHER2-pCR clinical trial (EA1181, NCT04266249). The findings help identify which early-stage HER2-positive (HER2+) breast cancers may be most likely to respond to less intensive chemotherapy than the current standard.
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedCoverage Context
More from Health
Continue reading recent Health coverage
- Early-onset menopause linked to increased symptoms of anxiety and depressionContinue reading
- An early start to flu season moves up vaccination timingContinue reading
- Exercise as medicine: How physical activity helps manage chronic diseaseContinue reading
- Inherited lupus can begin early—and continue silentlyContinue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow